Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer

Abstract

This NIS reports one of the largest mCRC collectives >65 years and reduced performance status. Cetuximab has a similar efficacy and safety profile for pts aged ≤ 65 and >65 years.